Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc., founded in 2015 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and developing a new class of medicines. These medicines target genetically determined dependencies within the chromatin regulatory system using Foghorn's proprietary Gene Traffic Control® Platform. This platform provides an integrated, mechanistic understanding of how various components of the chromatin regulatory system interact, allowing the identification, validation, and potential drugging of targets within the system.
The company's lead programs include FHD-286 and FHD-609. FHD-286 is a small-molecule enzymatic inhibitor of BRG1 and BRM, targeting acute myeloid leukemia (AML) and uveal melanoma. FHD-609 is a protein degrader of BRD9 aimed at treating synovial sarcoma. Additionally, Foghorn is developing preclinical and discovery programs such as selective BRM targeting non-small-cell lung cancer and selective ARID1B modulators for bladder, ovarian, and endometrial cancer.
Foghorn has established a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company's financial stability is reflected in its cash and equivalents of approximately $259.9 million as of September 30, 2023, which supports its robust pipeline and strategic objectives for 2024 and beyond.
Recent Achievements and Current Projects:
- Initiated a Phase 1 combination study of FHD-286 in AML with data expected in the second half of 2024.
- Progress with the selective BRM inhibitor FHD-909, with an IND planned for the second quarter of 2024, primarily targeting non-small cell lung cancer.
- Presented preclinical data showcasing selective CBP and EP300 degrader programs, demonstrating significant tumor growth inhibition without associated hematopoietic toxicity.
- Announced multiple strategic milestones, including financial updates and corporate outlooks, reflecting continued progress across various therapeutic programs.
The company remains committed to advancing its preclinical and clinical programs, supported by collaborations and financial investments, with the goal of developing novel medicines that can transform the lives of patients with serious diseases.
Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in Cowen’s 42nd Annual Health Care Conference, scheduled from March 7th to March 9th, 2022. The company will be featured in a panel addressing leukemias and myeloproliferative neoplasms on March 7th at 10:30 a.m. ET. Foghorn is engaged in developing innovative medicines that target genetic dependencies in the chromatin regulatory system, having multiple oncology product candidates, with two in clinical studies. A webcast of the panel will be available for 90 days post-event on their website.
Foghorn Therapeutics (FHTX) announced the promotion of Steven Bellon, Ph.D., to Chief Scientific Officer, effective January 10, 2022. Bellon, a pivotal figure in Foghorn's drug discovery efforts, succeeds Carl Decicco, Ph.D., who is retiring. CEO Adrian Gottschalk praised Decicco's contributions, highlighting the advancement of two clinical programs in 2021. Bellon has been with Foghorn since 2016 and has played a critical role in developing the company's Gene Traffic Control® platform and advancing its diverse therapeutic pipeline, including over 15 programs in oncology.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced its participation in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. The company will present on January 10, with availability for 90 days. Foghorn focuses on developing novel therapies aimed at genetically determined dependencies within the chromatin regulatory system, particularly in oncology. Its Gene Traffic Control Platform supports the identification of potential drug targets, with multiple candidates currently being investigated in clinical studies.
Foghorn Therapeutics has entered into a strategic collaboration with Loxo Oncology at Lilly to develop novel oncology medicines utilizing Foghorn's Gene Traffic Control platform. The agreement includes a co-development and co-commercialization deal for Foghorn's selective BRM oncology program and another undisclosed program, alongside three additional discovery programs. Foghorn will receive $300 million upfront, along with an $80 million equity investment from Lilly at $20 per share. The partnership could yield up to $1.3 billion in potential milestones.
Loxo Oncology at Lilly and Foghorn Therapeutics announced a strategic collaboration aimed at developing novel oncology drugs using Foghorn's Gene Traffic Control platform. The agreement entails a $300 million upfront payment and an $80 million equity investment from Lilly. Foghorn will lead early research for their BRM-selective program, while Lilly will manage development and commercialization. They will share U.S. economics 50/50 and Foghorn stands to earn up to $1.3 billion in potential milestones. This collaboration addresses BRG1 mutations in various cancers, impacting a significant patient population.
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company, will virtually participate in the 2021 Jefferies London Healthcare Conference. The event includes a presentation and investor 1x1 meetings, available on-demand from November 18, 2021, 8:00am GMT to November 19, 2021, 5:00pm GMT. Foghorn specializes in developing medicines that target the chromatin regulatory system and is advancing multiple oncology product candidates. For more details and the presentation access, visit www.foghorntx.com.
Foghorn Therapeutics (Nasdaq: FHTX) announced the dosing of the first patient in its phase 1 trial of FHD-609, a protein degrader targeting BRD9 for synovial sarcoma. The company is also advancing FHD-286, an inhibitor for metastatic uveal melanoma and relapsed AML. Recent highlights include participation in the Targeted Protein Degradation Summit and a financial update showing cash reserves of $120.8 million as of September 30, 2021. Foghorn plans to release initial data from both clinical programs in late 2021 and early 2022.
Foghorn Therapeutics (Nasdaq: FHTX) announced that its VP of Chemistry, David Millan, PhD, will present at the 4th Annual Targeted Protein Degradation Summit from October 26-29, 2021. Dr. Millan will discuss Foghorn's innovative protein degrader platform and its clinical asset, FHD-609, a heterobifunctional degrader of BRD9 aimed at treating synovial sarcoma. The company is advancing over eight protein degrader programs, with FHD-609 recently entering clinical trials, demonstrating potential in transforming treatment options for various cancers.
Foghorn Therapeutics (Nasdaq: FHTX) has announced its participation in two virtual investor conferences. The first is the Morgan Stanley Virtual Annual Global Healthcare Conference on September 9, 2021, featuring a fireside chat and one-on-one meetings. The second is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with a presentation and one-on-one meetings. Presentations will be available on-demand, and replays can be accessed for 90 days. Foghorn focuses on developing medicines that target the chromatin regulatory system in oncology.
Foghorn Therapeutics has announced the initiation of a first-in-human clinical trial for FHD-609, a selective protein degrader targeting BRD9, aimed at treating advanced synovial sarcoma. The trial marks a significant milestone for Foghorn's Gene Traffic Control platform, which focuses on addressing substantial unmet medical needs in oncology. FHD-609 seeks to exploit a synthetic lethal relationship with specific genetic mutations in synovial sarcoma. The company anticipates initial clinical data to be available in early 2022.
FAQ
What is the current stock price of Foghorn Therapeutics (FHTX)?
What is the market cap of Foghorn Therapeutics (FHTX)?
What is Foghorn Therapeutics Inc. focused on?
What are the main products under development by Foghorn Therapeutics?
What is the Gene Traffic Control® Platform?
What are some of the recent achievements of Foghorn Therapeutics?
What is Foghorn Therapeutics' financial condition?
Who are Foghorn Therapeutics' collaborators?
When was Foghorn Therapeutics founded?
Where is Foghorn Therapeutics headquartered?
What are Foghorn Therapeutics' key areas of research?
What is the strategic outlook for Foghorn Therapeutics in 2024?
